|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alkermes Inc., of Cambridge, Mass., said results of a Phase III extension study of Vivitrex (naltrexone long-acting injection) in alcohol-dependent patients show that the drug plus counseling led to a sustained reduction in heavy drinking over an 18-month period. The trial included 332 patients - about 85 percent of the subjects enrolled in the initial six-month study - who received Vivitrex in 380-mg or 190-mg doses. Those who continued on active treatment with 380 mg demonstrated a sustained reduction in levels of heavy drinking. The median number of heavy drinking days on Vivitrex treatment in the main trial was similar to the number during the 12-month extension ...
Related newspaper, magazine, and journal articles:
|
|
Article: OTHER NEWS TO NOTE.(Xanodyne Pharmaceuticals Inc)
BIOWORLD Today;
July 27, 2005 ;
700+ words
... ... patient enrollment in Europe in its pivotal Phase III trial of its lead drug, tilarginine acetate injection, to treat cardiogenic shock ... dose level and placebo. Axonyx halted a Phase III study of Phenserine, a selective acetylcholinesterase ...
|
|